Impact of synbiotics on liver health and metabolism in fatty liver disease
Official title: Gut Microbiota Profile Analysis and Randomized Controlled Trials (RCT) Study of the Effect of Synbiotics on Insulin and TNF-α in Metabolic Dysfunction -Associated Fatty Liver Disease (MAFLD)
Run by Universitas Diponegoro · NCT06585982 · Data updated 2026-11-12
This study is testing whether taking synbiotics can improve liver health and metabolism in people with fatty liver disease.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 25 Years to 55 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Universitas Diponegoro Academic / other |
| Locations | 1 site (Semarang, Semarang) |
| Status | Recruiting |
| Started | March 4, 2024 |
| Main results expected | March 7, 2025 |
| Study ends | March 7, 2025 |
| Registry record updated | November 12, 2024 |
| Trial ID | NCT06585982 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 25-55 years diagnosed with MAFLD who are willing to comply with the study requirements.
✕Probably not a fit
Patients with liver diseases such as hepatitis or cirrhosis, or those with a history of significant alcohol consumption, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effects of synbiotic supplementation on metabolic profiles, insulin levels, TNF-α, and gut microbiota in patients diagnosed with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). Participants will be divided into a treatment group receiving synbiotics and a control group receiving a placebo for 12 weeks, with follow-up visits every 28 days. The study aims to understand how synbiotics can influence liver health and metabolic functions in individuals with MAFLD.
Why it matters
Potential benefit: If successful, this study could provide a novel dietary intervention to improve liver health and metabolic outcomes in patients with fatty liver disease.
How similar studies have gone: Previous studies have shown promising results with synbiotics in improving liver health and metabolic profiles, indicating potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adult patients aged 25-55 years 2. Patients are willing to become research respondents after filling out informed consent 3. Patients can and are willing to consume supplements orally within a predetermined time 4. Patients are willing to record compliance with taking supplements in a diary that has been provided 5. Patients diagnosed with MAFLD by FibroScan interpreted by a specialist in gastroenterology-hepatology with a CAP score ≥263 dB/m Exclusion Criteria: 1. Patients with hepatitis (hepatitis B, hepatitis C, and autoimmune hepatitis) and alcoholic liver disease, cirrhosis of the liver 2. Patients who are pregnant, or breastfeeding or in a programme to become pregnant during participation in this study. 3. Patients with a history of alcohol consumption \>40 g/day. 4. Patients with a history of decompensated disease including ascites, encephalopathy, variceal haemorrhage 5. Patients with Hepatocellular Carcinoma (HCC) 6. Patients with a history of bowel resection or bariatric surgery Patients with chronic inflammatory bowel disease (IBD) 7. Patients with a history of antibiotic use or probiotic/prebiotic/synbiotic consumption in the past 1 month 8. Use of Vitamin E and omega-3 fatty acids 9. Patients who were not hospitalised in the last month and therefore did not have any food restrictions related to their illness.
Where it's running
-
RSUP Dr. Kariadi
Semarang, Semarang, Indonesia Recruiting
Study contacts
- Principal investigator: Hery D Purnomo, Dr — Dr. Kariadi Medical Hospital
- Study coordinator: Hery D Purnomo, Dr
- Email: herydjagat@yahoo.co.id
- Phone: +628122803136
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
NMR-based Risk Test and Digital Health Support for midlife adults in Eloisa
This study tests whether an NMR metabolomics risk test can guide tailored digital health programs for midlife adults at risk of diabetes, heart disease, stroke, kidney disease, or fatty liver.
-
Gepaktiv compared with UDCA and Ademetionine for MAFLD with enlarged liver
This study will try the dietary supplement Gepaktiv to see if it improves liver enzymes, liver size, and fat in adults with MAFLD and hepatomegaly compared with UDCA and ademetionine.
-
Evaluating LivQ-box® for diagnosing liver inflammation
This study is testing if the LivQ-box® can help doctors better diagnose liver inflammation in people with nonalcoholic fatty liver disease.
-
Investigating how sugars affect fat accumulation in the liver
This study tests how different types of sugars affect fat buildup in the liver of men, both non-obese and obese, to help understand better ways to manage liver health.
-
Digoxin for NASH with stage 2–3 fibrosis
This trial will see if taking once-daily digoxin helps clear NASH and reduce liver scarring in adults with biopsy-confirmed NASH and stage 2–3 fibrosis.
-
Investigating the effects of Cushing's syndrome on fatty liver disease
This study is testing how Cushing's syndrome affects the risk of developing fatty liver disease in adults who have the condition.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.